Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate

被引:38
|
作者
Gamsjaeger, Sonja [1 ]
Buchinger, Birgit [1 ]
Zoehrer, Ruth [1 ]
Phipps, Roger [2 ]
Klaushofer, Klaus [1 ]
Paschalis, Eleftherios P. [1 ]
机构
[1] Hanusch Hosp, Ludwig Boltzmann Inst Osteol, WGKK & AUVA Trauma Ctr Meidling, Dept Med 1, A-1140 Vienna, Austria
[2] Procter & Gamble Pharmaceut, Mason, OH USA
关键词
Teriparatide; Alendronate; Risedronate; Bone material properties; Fourier transform infrared imaging; Raman Microspectroscopy; Mineral maturity; Collagen cross-links; ILIAC CREST BIOPSIES; FTIR MICROSPECTROSCOPIC ANALYSIS; PARATHYROID-HORMONE; AMERICAN-SOCIETY; MINERAL DENSITY; TASK-FORCE; QUALITY; OSTEONECROSIS; JAW; HYDROXYAPATITE;
D O I
10.1016/j.bone.2011.08.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the present work we examined the effect of teriparatide administration following bisphosphonate treatment on bone compositional properties by Raman and Fourier Transform Infrared Imaging (FTIR) microspectroscopic analysis. Thirty two paired iliac crest biopsies (before and after 1 year teriparatide) from sixteen osteoporotic women previously treated with either Alendronate (ALN) or Risedronate (RIS) and subsequently treated 12 months with teriparatide (TPTD) were analyzed at anatomical areas of similar tissue age in bone forming areas (within the fluorescent double labels). The outcomes that were monitored and reported were mineral to matrix ratio (corresponding to ash weight), mineral maturity (indicative of the mineral crystallite chemistry and stoichiometry, and having a direct bearing on crystallite shape and size), relative proteoglycan content (regulating mineralization commencement), and the ratio of two of the major enzymatic collagen cross-links (pyridinoline/divalent). Significant differences in mineral/matrix, mineral maturity/crystallinity, and collagen cross-link ratio bone quality indices after TPTD treatment were observed, indicating a specific response of these patients to TPTD treatment. Moreover differences between ALN and RIS treated patients at baseline in the collagen cross-link ratio were observed. Since tissue areas of similar tissue age were analyzed, these differences may not be attributed to differences in bone turnover. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1160 / 1165
页数:6
相关论文
共 50 条
  • [31] APPLICATION OF QUANTITATIVE BONE SCAN USING KBONE VALUES TO IDENTIFY REGIONAL BONE METABOLISM CHANGES IN POSTMENOPAUSAL OSTEOPOROTIC WOMEN TREATED EITHER WITH ALENDRONATE OR TERIPARATIDE
    Garg, B.
    Dixit, V.
    Parida, G.
    Sati, H.
    Kumar, R.
    Malhotra, R.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S610 - S611
  • [32] APPLICATION OF QUANTITATIVE BONE SCAN USING KBONE VALUES TO IDENTIFY REGIONAL BONE METABOLISM CHANGES IN POSTMENOPAUSAL OSTEOPOROTIC WOMEN TREATED EITHER WITH ALENDRONATE OR TERIPARATIDE
    Garg, B.
    Dixit, V.
    Parida, G.
    Sen, S.
    Sati, H. C.
    Kumar, R.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S166 - S166
  • [33] COMPARISON OF RISEDRONATE AND ALENDRONATE ON BONE REMODELING, ARCHITECTURE, AND MATERIAL PROPERTIES: A CROSS-SECTIONAL STUDY IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS
    Paschalis, Eleftherios
    Phipps, Roger
    Ebetino, Frank
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : 232 - 232
  • [34] Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters
    Arlot, M
    Meunier, PJ
    Boivin, G
    Haddock, L
    Tamayo, J
    Correa-Rotter, R
    Jasqui, S
    Donley, DW
    Dalsky, GP
    San Martin, J
    Eriksen, EF
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (07) : 1244 - 1253
  • [35] Continuous treatment of postmenopausal osteoporotic Greek women with risedronate and its effect on bone markers
    Koulouris, I. C. H.
    Kataxaki, E.
    Antipas, G.
    Makris, A.
    Metania, E.
    Mamalis, K.
    Konstantelous, E.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S233 - S233
  • [36] Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis
    Aysegul Atmaca
    Olcay Gedik
    Advances in Therapy, 2006, 23 : 842 - 853
  • [37] Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis
    Atmaca, Aysegul
    Gedlik, Olcay
    ADVANCES IN THERAPY, 2006, 23 (06) : 842 - 853
  • [38] Comparison of Bone and Total Alkaline Phosphatase and Bone Mineral Density in Postmenopausal Osteoporotic Women Treated with Alendronate
    N. B. Watts
    D. K. Jenkins
    J. M. Visor
    D. C. Casal
    P. Geusens
    Osteoporosis International, 2001, 12 : 279 - 288
  • [39] Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate
    Watts, NB
    Jenkins, DK
    Visor, JM
    Casal, DC
    Geusens, P
    OSTEOPOROSIS INTERNATIONAL, 2001, 12 (04) : 279 - 288
  • [40] Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis
    Kucukalic-Selimovic, Elma
    Valjevac, Amina
    Hadzovic-Dzuvo, Almira
    Skopljak-Beganovic, Amra
    Alimanovic-Alagic, Rubina
    Brkovic, Amera
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2011, 11 (01) : 41 - 45